Swiss drugmaker Novartis is set to acquire a promising breast cancer drug candidate from US biotech firm Synnovation Therapeutics. The deal is valued at up to three billion dollars. This acquisition bolsters Novartis's pipeline of targeted cancer therapies. The experimental drug, SNV4818, targets a specific type of breast cancer.